CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cardiovascular Systems, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cardiovascular Systems, Inc.
1225 Old Hwy 8 Nw
Phone: (651) 259-1600p:651 259-1600 ST. PAUL, MN  55112  United States Fax: (612) 677-3355f:612 677-3355
This company was Merged or Acquired on 4/27/2023.
This company ceased filing statements with the SEC on 5/8/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20226/30/2022YesYes--Yes

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
3845 Electromedical and electrotherapeutic apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Scott R.Ward 62 8/16/2016 11/1/2013
Chief Financial Officer Jeffrey S.Points 45 2/1/2018 7/1/2007
Chief Human Resource Officer Stephen J.Rempe 49 7/1/2020 5/1/2019
8 additional Officers and Directors records available in full report.

Business Names
Business Name
altiCardiovascular Systems, Inc.
CardioVascular Systems, Inc.
CSII
REPLIDYNE INC
Replidyne, Inc
Replidyne, Inc.

General Information
Number of Employees: 725 (As of 6/30/2022)
Outstanding Shares: 42,198,048 (As of 3/14/2023)
Shareholders: 78
Stock Exchange: NASD
Federal Tax Id: 841568247
Fax Number: (612) 677-3355
Email Address: contact@replidyne.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2024